Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Emory and Eurofins, following their JV last year, plan to open several clinical genetics labs across the globe that draw on EGL's expertise.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.
DiaGenomi offers a number of tests that combine DNA analysis with information about lifestyle and medical results to provide disease risk assessments.
A private financing fell short of its goal and the IDL joint venture has been unable to its obligations to GeneNews and Cobalt Healthcare, the owners of the JV.
In the second quarter, Quest reported revenues of $1.93 billion and estimated 2015 revenues will be between $7.49 billion and $7.57 billion.
The firms aim to establish the second largest lab services firm in the world to aid drugmakers with clinical trials.
The joint venture will leverage Qiagen's ModaPlex platform to develop assays initially for personalized healthcare applications.
In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.
Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.
Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.
British researchers say they've been removed from EU grant applications, according to the Guardian.